The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L02 | Endocrine therapy | |
| 3 | L02A | Hormones and related agents | |
| 4 | L02AB | Progestogens |
| Code | Title | |
|---|---|---|
| L02AB01 | Megestrol | |
| L02AB02 | Medroxyprogesterone | |
| L02AB03 | Gestonorone |
| Active Ingredient | Description | |
|---|---|---|
| Medroxyprogesterone |
Medroxyprogesterone acetate exerts anti-oestrogenic, anti-androgenic and antigonadotrophic effects. |
|
| Megestrol |
Megestrol possesses pharmacological properties similar to those of natural progesterone. Megestrol acetate is a potent progestogen that exerts significant anti-oestrogenic effects. It has no androgenic or oestrogenic properties. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| DEPO-PROVERA Suspension for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| MEGACE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
| PROVERA Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
